Yi 2020.

Study characteristics
Notes	English title Risk factors and clinical features of deterioration in COVID‐19 patients in Zhejiang, China: a single‐centre, retrospective study Study setting Start of study recruitment (MM/YYYY): 01/2020 End of study recruitment (MM/YYYY): 02/2020 Study design: Retrospective cohort Study centre(s): Single centre/clinic/area within a country Number of centres, clinics or areas: 1 Study setting: Inpatient Number of participants recruited: 100 Sampling method: NR Participants Female participants (absolute number): 37 Age measure, value: Median (IQR), 54 (42, 64) Inclusion criteria: All patients diagnosed with SARS‐CoV‐2 who were admitted to the First Affiliated Hospital of Zhejiang University School of Medicine between January 19, 2020, and February 19, 2020 Exclusion criteria: NR Smoking frequency: NR Diabetes frequency: 11 Hypertension frequency: 37 Cardiovascular disease frequency: 4 Asthma frequency: NR Chronic obstructive pulmonary disease frequency: NR Other pulmonary disease frequency: NR Immunosuppression frequency: NR Chronic kidney disease frequency: NR Cancer frequency: NR Steroid administration frequency: 81 Supplemental oxygen administration frequency: 100 Other treatments (frequency): NR Prognostic factor(s) Study’s definition for obesity: NR The time when obesity has been measured: Before disease or right at presentation Main variable used for determination of obesity: BMI Threshold used for definition: NR Obesity frequency (absolute number): NR Prognostic factor(s): BMI continuous Outcome(s) Severe COVID Outcome (prognostic factor) Severe COVID (BMI continuous) Follow‐up Number of patients followed completely for the outcome: 100 Number of obese patients followed completely for the outcome: NR Number of non‐obese patients followed completely for the outcome: NR Univariable unadjusted analysis for obesity Effect measure for obesity: NR Effect measure value (95% CI), P value: NR Multivariable analysis for obesity Modelling method: Logistic regression The set of prognostic factors used for adjustment: Age, sex, hypertension, IL‐6, T‐lymphocyte count, B‐lymphocyte count, glucocorticoid treatment and artificial liver support Effect measure for obesity: Odds ratio Effect measure value (95% CI), P value: 1.24 (1.006, 1.52), < 0.044
Item	Authors' judgement	Support for judgement
Study Participation	Unclear	Appendix 3
Study Attrition Severe COVID	Yes	Appendix 3
Prognostic Factor Measurement	Yes	Appendix 3
Outcome Measurement Severe COVID	Yes	Appendix 3
Confounding Bias Severe COVID	Unclear	Appendix 3
Statistical Analysis Bias	Yes	Appendix 3